Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 14, 2014 - Issue 2
Submit an article Journal homepage
150
Views
5
CrossRef citations to date
0
Altmetric
Special Report

We know how to prescribe natalizumab for multiple sclerosis, but do we know how to withdraw it?

Yara D FragosoMS Reference Center, Medical School, Universidade Metropolitana de Santos, Santos, SP, Brazil;Department of Neurology, Medical School, Universidade Metropolitana de Santos, Rua da Constituicao 374, CEP 11015-470, Santos, SP, BrazilCorrespondence[email protected]
,
Niedja M ArrudaDemyelinating Diseases Reference Center, Hospital da Restauração, Recife, PE, Brazil
,
Walter O ArrudaMS Unit, Medical School, Universidade Federal do Paraná, Curitiba, PR, Brazil
,
Joseph BB BrooksMS Reference Center, Medical School, Universidade Metropolitana de Santos, Santos, SP, Brazil
,
Eber C CorreaMS Unit, CLINEN – Neurologia e Endocrinologia, Brasília, DF, Brazil
,
Alfredo DamascenoMS Reference Center, Medical School, Universidade Estadual de Campinas, Campinas, SP, Brazil
,
Carlos A DamascenoMS Unit, Medical School, Universidade Federal de Juiz de Fora, Juiz de Fora, MG, Brazil
,
Maria LB FerreiraDemyelinating Diseases Reference Center, Hospital da Restauração, Recife, PE, Brazil
,
Maria CB GiacomoMS Unit, Holus Medical Services, São Paulo, SP, Brazil
,
Sidney GomesMS Unit, Hospital Beneficência Portuguesa and Hospital Paulistano, São Paulo, SP, Brazil
,
Marcus VM GonçalvesMS Unit, Centro Hospitalar Unimed, Joinville, SC, Brazil
,
Anderson K GrzesiukMS Reference Center, Centro de Reabilitação Dom Aquino Correa, Cuiaba, MT, Brazil
,
Damacio R Kaimen-MacielMS Reference Center, Medical School, Universidade Estadual de Londrina, Londrina, PR, Brazil
,
Josiane LopesMS Reference Center, Medical School, Universidade Estadual de Londrina, Londrina, PR, Brazil
,
Suzana CN MachadoMS Reference Center, Imperial Hospital de Caridade, Hospital Governador Celso Ramos, Florianopolis, SC, Brazil
,
Celso LS OliveiraMS Reference Center, Medical School, Universidade Metropolitana de Santos, Santos, SP, Brazil
&
Carla RAV StellaMS Unit, Neurology, Campinas, SP, Brazil
 show all
Pages 127-130 | Published online: 13 Jan 2014

References

  • Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest 2012;122:1180-8
  • McCoyd M. Update on therapeutic options for multiple sclerosis. Neurol Clin 2013;31:827-45
  • McCormack PL. Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis. Drugs 2013;73(13):1463-81
  • Fernández O. Best practice in the use of natalizumab in multiple sclerosis. Ther Adv Neurol Disord 2013;6:69-79
  • Sørensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012;18:143-52
  • Pucci E, Giuliani G, Solari A, et al. Natalizumab for relapsing remitting multiple sclerosis. Cochrane Database Syst Rev 2011;10:CD007621
  • Fragoso YD, Alves-Leon SV, Arruda WO, et al. Natalizumab adverse events are rare in patients with multiple sclerosis. Arq Neuropsiquiatr 2013;71:137-41
  • Damasceno A, von Glehn F, Martinez AR, et al. Early onset of natalizumab-related progressive multifocal leukoencephalopathy. Mult Scler 2011;17:1397-8
  • Baumgartner A, Stich O, Rauer S. Clinical and radiological disease reactivation after cessation of long-term therapy with natalizumab. Int J Neurosci 2012;122:35-9
  • Rigau V, Mania A, Béfort P, et al. Lethal multiple sclerosis relapse after natalizumab withdrawal. Neurology 2012;79:2214-16
  • Marousi S, Travasarou M, Karageorgiou CE, et al. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology 2012;79:2160
  • Berger JR, Centonze D, Comi G, et al. Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Ann Neurol 2010;68:409-11
  • Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 2011;68:186-91
  • Borriello G, Prosperini L, Marinelli F, et al. Observations during an elective interruption of natalizumab treatment: a post-marketing study. Mult Scler 2011;17:372-5
  • Papeix C, Depaz R, Tourbah A, et al. Dramatic worsening following plasma exchange in severe post-natalizumab withdrawal multiple sclerosis relapse. Mult Scler 2011;17:1520-2
  • Borriello G, Prosperini L, Mancinelli C, et al. Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study. Eur J Neurol 2012;19:783-7
  • Magraner MJ, Coret F, Navarré A, et al. Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study. J Neurol 2011;258:1805-11
  • Rossi S, Motta C, Studer V, et al. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab. Eur J Neurol 2013;20:87-94
  • Havla J, Gerdes LA, Meinl I, et al. De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol 2011;258:1665-9
  • Gobbi C, Meier DS, Cotton F, et al. Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. BMC Neurol 2013;13:101
  • Cree B, De Seze J, Fox R, et al. RESTORE Study: effects of a 24-week natalizumab treatment interruption on immune parameters and multiple sclerosis magnetic resonance imaging disease activity 2012; (P06.168). Neurology 2012;78(Meeting Abstracts 1):P06.168
  • Comi G, Gold R, Dahlke F, et al. Overall safety and relapse outcomes in fingolimod-treated patients previously treated with natalizumab in the 4-month, open-label FIRST study [Poster 537]. 23rd European Neurology Society (ENS) Meeting, Barcelona, Spain; 2013
  • Havla J, Tackenberg B, Hellwig K, et al. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis. J Neurol 2013;260:1382-7
  • Daelman L, Maitrot A, Maarouf A, et al. Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal. Mult Scler 2012;11:1647-9
  • Sempere AP, Martín-Medina P, Berenguer-Ruiz L, et al. Switching from natalizumab to fingolimod: an observational study. Acta Neurol Scand 2013;128:e6-e10
  • Centonze D, Rossi S, Rinaldi F, Gallo P. Severe relapses under fingolimod treatment prescribed after natalizumab. Neurology 2012;79:2004-5
  • Jander S, Turowski B, Kieseier BC, Hartung HP. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler 2012;18:1650-2

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.